Penpulimab and Anlotinib in PDL1 high-expression pulmonary giant cell carcinoma with cerebral metastases: case report and review
Pulmonary giant cell carcinoma (PGCC) is a rare subtype of non-small cell lung cancer (NSCLC) characterized by complex pathology, high rates of misdiagnosis or missed diagnosis, an aggressive clinical course, rapid progression, and poor prognosis. This case report describes a 67-year-old Chinese mal...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1476205/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850244165897551872 |
|---|---|
| author | Minghong Xie Yunlong Zhao Xiaohua Hou Ning Li Sha Niu Xinju Xu |
| author_facet | Minghong Xie Yunlong Zhao Xiaohua Hou Ning Li Sha Niu Xinju Xu |
| author_sort | Minghong Xie |
| collection | DOAJ |
| description | Pulmonary giant cell carcinoma (PGCC) is a rare subtype of non-small cell lung cancer (NSCLC) characterized by complex pathology, high rates of misdiagnosis or missed diagnosis, an aggressive clinical course, rapid progression, and poor prognosis. This case report describes a 67-year-old Chinese male with a left upper lobe lung mass, diagnosed via CT-guided lung biopsy as PGCC with symptomatic multiple cerebral metastases. The tumor showed strong PD-L1 positivity, and genetic testing revealed a TP53 exon 4 c.313G mutation. Treatment involved first-line therapy with Penpulimab injection combined with Anlotinib and concurrent cranial radiotherapy. Significant reduction in both the pulmonary and cerebral metastatic lesions was observed, with notable efficacy. As of June 2024, there has been no disease progression for 26 months, with the patient currently maintained on Anlotinib monotherapy. This case demonstrates the favorable efficacy of Penpulimab injection combined with Anlotinib in treating advanced PGCC. These findings indicate that this combination therapy may offer a promising new therapeutic option for this rare type of lung cancer. |
| format | Article |
| id | doaj-art-cbe377f2c30a42509ad581173e0fec8f |
| institution | OA Journals |
| issn | 2234-943X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-cbe377f2c30a42509ad581173e0fec8f2025-08-20T01:59:48ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-12-011410.3389/fonc.2024.14762051476205Penpulimab and Anlotinib in PDL1 high-expression pulmonary giant cell carcinoma with cerebral metastases: case report and reviewMinghong Xie0Yunlong Zhao1Xiaohua Hou2Ning Li3Sha Niu4Xinju Xu5Department of Respiratory and Critical Care Medicine, First Affiliated Hospital of Henan Polytechnic University, Jiaozuo Second People’s Hospital, Jiaozuo, ChinaDepartment of Pathology, First Affiliated Hospital of Henan Polytechnic University, Jiaozuo Second People’s Hospital, Jiaozuo, Henan, ChinaDepartment of Respiratory and Critical Care Medicine, First Affiliated Hospital of Henan Polytechnic University, Jiaozuo Second People’s Hospital, Jiaozuo, ChinaDepartment of Respiratory and Critical Care Medicine, First Affiliated Hospital of Henan Polytechnic University, Jiaozuo Second People’s Hospital, Jiaozuo, ChinaDepartment of Respiratory and Critical Care Medicine, First Affiliated Hospital of Henan Polytechnic University, Jiaozuo Second People’s Hospital, Jiaozuo, ChinaDepartment of Respiratory and Critical Care Medicine, First Affiliated Hospital of Henan Polytechnic University, Jiaozuo Second People’s Hospital, Jiaozuo, ChinaPulmonary giant cell carcinoma (PGCC) is a rare subtype of non-small cell lung cancer (NSCLC) characterized by complex pathology, high rates of misdiagnosis or missed diagnosis, an aggressive clinical course, rapid progression, and poor prognosis. This case report describes a 67-year-old Chinese male with a left upper lobe lung mass, diagnosed via CT-guided lung biopsy as PGCC with symptomatic multiple cerebral metastases. The tumor showed strong PD-L1 positivity, and genetic testing revealed a TP53 exon 4 c.313G mutation. Treatment involved first-line therapy with Penpulimab injection combined with Anlotinib and concurrent cranial radiotherapy. Significant reduction in both the pulmonary and cerebral metastatic lesions was observed, with notable efficacy. As of June 2024, there has been no disease progression for 26 months, with the patient currently maintained on Anlotinib monotherapy. This case demonstrates the favorable efficacy of Penpulimab injection combined with Anlotinib in treating advanced PGCC. These findings indicate that this combination therapy may offer a promising new therapeutic option for this rare type of lung cancer.https://www.frontiersin.org/articles/10.3389/fonc.2024.1476205/fullpulmonary giant cell carcinomaPenpulimab injectionAnlotinibcerebral metastasesPD-L1 positivity |
| spellingShingle | Minghong Xie Yunlong Zhao Xiaohua Hou Ning Li Sha Niu Xinju Xu Penpulimab and Anlotinib in PDL1 high-expression pulmonary giant cell carcinoma with cerebral metastases: case report and review Frontiers in Oncology pulmonary giant cell carcinoma Penpulimab injection Anlotinib cerebral metastases PD-L1 positivity |
| title | Penpulimab and Anlotinib in PDL1 high-expression pulmonary giant cell carcinoma with cerebral metastases: case report and review |
| title_full | Penpulimab and Anlotinib in PDL1 high-expression pulmonary giant cell carcinoma with cerebral metastases: case report and review |
| title_fullStr | Penpulimab and Anlotinib in PDL1 high-expression pulmonary giant cell carcinoma with cerebral metastases: case report and review |
| title_full_unstemmed | Penpulimab and Anlotinib in PDL1 high-expression pulmonary giant cell carcinoma with cerebral metastases: case report and review |
| title_short | Penpulimab and Anlotinib in PDL1 high-expression pulmonary giant cell carcinoma with cerebral metastases: case report and review |
| title_sort | penpulimab and anlotinib in pdl1 high expression pulmonary giant cell carcinoma with cerebral metastases case report and review |
| topic | pulmonary giant cell carcinoma Penpulimab injection Anlotinib cerebral metastases PD-L1 positivity |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1476205/full |
| work_keys_str_mv | AT minghongxie penpulimabandanlotinibinpdl1highexpressionpulmonarygiantcellcarcinomawithcerebralmetastasescasereportandreview AT yunlongzhao penpulimabandanlotinibinpdl1highexpressionpulmonarygiantcellcarcinomawithcerebralmetastasescasereportandreview AT xiaohuahou penpulimabandanlotinibinpdl1highexpressionpulmonarygiantcellcarcinomawithcerebralmetastasescasereportandreview AT ningli penpulimabandanlotinibinpdl1highexpressionpulmonarygiantcellcarcinomawithcerebralmetastasescasereportandreview AT shaniu penpulimabandanlotinibinpdl1highexpressionpulmonarygiantcellcarcinomawithcerebralmetastasescasereportandreview AT xinjuxu penpulimabandanlotinibinpdl1highexpressionpulmonarygiantcellcarcinomawithcerebralmetastasescasereportandreview |